XIAP Is a Predictor of Cisplatin-Based Chemotherapy Response and Prognosis for Patients with Advanced Head and Neck Cancer

BACKGROUND: Approximately 60–80% of patients with advanced head and neck squamous cell carcinoma (HNSCC) die within five years after diagnosis. Cisplatin-based chemotherapy is the most commonly used palliative treatment for these patients. To evaluate the prognostic value of X-linked inhibitor of ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xi-Hu, Feng, Zhi-En, Yan, Ming, Hanada, Sayaka, Zuo, Hui, Yang, Cheng-Zhe, Han, Ze-Guan, Guo, Wei, Chen, Wan-Tao, Zhang, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293890/
https://www.ncbi.nlm.nih.gov/pubmed/22403616
http://dx.doi.org/10.1371/journal.pone.0031601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293890/
https://www.ncbi.nlm.nih.gov/pubmed/22403616
http://dx.doi.org/10.1371/journal.pone.0031601

Ejemplares similares